In the Acknowledgements section of this article the last sentence, which previously read: “Medical writing was funded through a donation by AbbVie Srl.” should have read: “Medical writing was funded by SIDeMaST.” The original article has been corrected.
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation / A. Chiricozzi, M. Ortoncelli, D. Schena, N. Gori, S.M. Ferrucci, G. Babino, M. Napolitano, M.C. Fargnoli, L. Stingeni, M. Rossi, M. Romanelli, R. Balestri, M. Pellegrino, A. Parodi, A.M. Bertoldi, G. Palazzo, F. Antonelli, A. Pitino, G. Tripepi, G. Fabbrocini, A. Balato, A.V. Marzano, G. Girolomoni, S. Ribero, K. Peris. - In: AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. - ISSN 1175-0561. - 24:6(2023), pp. 963-964. [10.1007/s40257-023-00813-4]
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
A.V. Marzano;
2023
Abstract
In the Acknowledgements section of this article the last sentence, which previously read: “Medical writing was funded through a donation by AbbVie Srl.” should have read: “Medical writing was funded by SIDeMaST.” The original article has been corrected.
| File | Dimensione | Formato | |
|---|---|---|---|
|
40257_2023_Article_813.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Licenza:
Creative commons
Dimensione
304.25 kB
Formato
Adobe PDF
|
304.25 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
